Targeted Protein Degradation continues to progress as a therapeutic with huge potential, and 2023 is shaping up to be a landmark year for the degradation community. With the emergence of over 88 newly disclosed TPD drugs in the first half of 2022 and over 67 TPD drug updates and critical collaborations – this community continues to advance highly valuable degrader compounds closer to the clinic.